Table 2.

Patient demographics and treatment information for untreated DLBCL patients

Patient	Sex	Age, y	Total cycles of chemotherapy	WBC, × 109/L	ALC, × 109/L	Absolute CD3, per μL	Absolute CD4, per μL	Absolute CD8, per μL	Absolute CD19, per μL	Absolute CD56, per μL	Absolute CD16, per μL
1*	M	55	0	8.1	2.660	1085	933	107	N/A	N/A	N/A
2*	F	51	0	8.8	2.675	2517	1734	604	N/A	N/A	N/A
3	F	75	0	8.5	1.173	652	538	91	N/A	N/A	N/A
4*	M	70	0	15.1	6.886	4968	4645	247	N/A	N/A	N/A
5	F	67	0	8.5	3.332	2465	1038	789	N/A	N/A	N/A
		67	0	8.5	2.675	2465	1038	247	N/A	N/A	N/A

The bottom row shows median values. All procedures were approved by the Institutional Review Board of Emory University (approval IRB0716).

^*Paired samples pre- and posttreatment.